On March 7, 2019 Helix BioPharma Corp. (TSX: HBP), (FSE: HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, is reported the first patient has been successfully dosed with L-DOS47, vinorelbine and cisplatin in its Phase IIB, open-label, randomized study in metastatic lung adenocarcinoma patients (LDOS003 study) (Press release, Helix BioPharma, MAR 7, 2019, View Source [SID1234536458]). The goals of the study are to compare the safety, tolerability and preliminary efficacy of L-DOS47 in combination with vinorelbine/cisplatin as compared to vinorelbine/cisplatin alone, in patients with lung cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The LDOS003 study involves two parts: In Part 1 of the study (dose escalation), patients in cohorts will receive escalating amount of L-DOS47 in combination with vinorelbine/cisplatin. Once the maximum tolerated dose of L-DOS47 as an adjunct to vinorelbine/cisplatin is determined, patients in Part 2 of the study (randomized treatment) will be randomly assigned to receive L-DOS47 in combination with vinorelbine/cisplatin or vinorelbine/cisplatin alone. Additional information about the trial can be found in the EU Clinical Trials Register (View Source).

"This is our second chemo-combination study for L-DOS47 in advanced non-small lung cancer study," said Dr. Heman Chao Ph.D., Chief Executive Officer of Helix. "We are very excited to see that L-DOS47 continues to advance in this disease indication.